問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 110Taipei CitySin Yi

Recruiting Trial

241Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

444Cases

2025-06-01 - 2027-12-31

Phase III

Active
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low-Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

  • Condition/Disease

    Atherosclerotic Cardiovascular Disease

  • Test Drug

    tablet

Participate Sites
8Sites

Recruiting8Sites

2025-03-01 - 2028-12-31

Phase II

Active
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids

  • Condition/Disease

    Asthma

  • Test Drug

    Tozorakimab

Participate Sites
8Sites

Recruiting8Sites

2022-01-01 - 2026-12-31

Phase III

Active
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA)

  • Condition/Disease

    Chronic Obstructive Pulmonary Disease

  • Test Drug

    MEDI3506

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2021-02-25 - 2024-06-05

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-02-01 - 2026-12-31

Phase I

Active
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

  • Condition/Disease

    Advanced or Metastatic NSCLC

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2020-09-15 - 2025-12-31

Phase III

Completed
A randomized, double-blind, double-dummy, parallel grouping, multi-center 24 to 52-week variable length trial designed to evaluate Budesonide, Glycopyrronium, and Formoterol Fumarate metered-dose inhalers (MDI) relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressure MDI, the efficacy and safety of adult and adolescent participants with poor asthma control (KALOS)

  • Condition/Disease

    Adults and adolescents with poor asthma control

  • Test Drug

    BGF MDI

Participate Sites
12Sites

Recruiting12Sites

2021-08-31 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Not yet recruiting9Sites

Recruiting9Sites

2022-05-01 - 2023-07-21

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting2Sites

Terminated6Sites

2025-04-01 - 2026-04-01

Others

Not yet recruiting
劑量調定的維生素D增補策略對馬拉松比賽後免疫功能與肌肉損傷的影響

  • Condition/Disease

    免疫功 能與肌肉損傷

  • Test Drug

    injection

Participate Sites
1Sites

Recruiting1Sites

2020-08-01 - 2024-07-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 5 6 7 8 9 45
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB